News
A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...
“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly’s chief scientific officer. “The safety, tolerability, and efficacy were ...
Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...
Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the ...
Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...
Despite reporting better-than-expected Q2 results, Eli Lilly is under pressure amid concerns over late-stage trial data for ...
24/7 Wall St. on MSN1d
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback